Michael E. Belloy, PhD; Yann Le Guen, PhD; Ilaria Stewart, BA; et al.
open access
JAMA Neurol. 2024;81(10):1032-1042. doi:10.1001/jamaneurol.2024.2843
This genetic association study evaluates the association between the X chromosome and Alzheimer disease.
Rui Li, MD, PhD; Chunrong Tao, MD, PhD; Jun Sun, MPH; et al.
JAMA Neurol. 2024;81(10):1043-1050. doi:10.1001/jamaneurol.2024.2652
This secondary analysis of a randomized clinical trial assesses 1-year clinical outcomes following endovascular thrombectomy in patients with acute basilar artery occlusion.
Laura E. M. Wisse, PhD; Nicola Spotorno, PhD; Marcello Rossi, PhD; et al.
JAMA Neurol. 2024;81(10):1051-1059. doi:10.1001/jamaneurol.2024.2713
This cohort study investigates the association between cerebrospinal fluid seed amplification α-synuclein positivity and magnetic resonance imaging (MRI) structural measures across the continuum from clinically unimpaired to cognitively impaired individuals.
Lars Wessels, MD; Stefan Wolf, MD; Tiziana Adage, PhD; et al.
open access
has audio
JAMA Neurol. 2024;81(10):1060-1065. doi:10.1001/jamaneurol.2024.2564
This randomized clinical trial investigated the safety and efficacy of nicardipine release implants for preventing proximal angiographic vasospasm after aneurysmal subarachnoid hemorrhage.
-
Podcast:
Localized Nicardipine Release Implants for Prevention of Vasospasm
Lei Liu, MD, PhD; Adriana Saba, MSc; Jesse R. Pascual, BS; et al.
JAMA Neurol. 2024;81(10):1066-1072. doi:10.1001/jamaneurol.2024.2579
This study investigates the binding properties of lecanemab in the brains of people with Down syndrome, in anticipation of their inclusion in clinical trials or access to antiamyloid immunotherapies.
Young Nam Kwon, MD, PhD; Boram Kim, MS; Jun-Soon Kim, MD; et al.
JAMA Neurol. 2024;81(10):1073-1084. doi:10.1001/jamaneurol.2024.2811
This cohort study evaluates if the time to treat the first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is associated with the disease course and seronegative conversion of anti–myelin oligodendrocyte glycoprotein immunoglobulin G.